These results led to the FDA-approval of pembrolizumab as first-line monotherapy in patients with recurrent or metastatic disease with PD-L1 CPS ≥1, and in combination with chemotherapy independently of PD-L1 expression (47). Here, CD274 is linked to metastatic neoplasm.